Lilly’s tirzepatide leads to body weight reductions in type 2 diabetes trial
Eli Lilly and Company has reported that results from the SURPASS-2 clinical trial of tirzepatide showed superior A1C and body…
05 Mar 2021
Apollomics begins dosing in Phase I AML treatment trial in China
Apollomics has dosed the first patient in a Phase I clinical trial of an investigational drug candidate, APL-106 (uproleselan injection), for treating adults with relapsed or refractory acute myeloid leukaemia…
05 Mar 2021
Dicerna and Roche start Phase II trial of GalXC RNAi candidate in hepatitis B
Dicerna Pharmaceuticals and Roche have commenced the Phase II combination trial of investigational GalXC RNAi candidate, RG6346, for treating chronic hepatitis B virus (HBV) infection. RG6346 is being developed by…
04 Mar 2021
Marker Therapeutics treats first subject in acute myeloid leukaemia trial
Marker Therapeutics has treated the first patient in its Phase II trial of its lead MultiTAA-specific T cell product candidate MT-401 in patients with acute myeloid leukaemia (AML). The multi-center…
04 Mar 2021
Lilly’s baricitinib meets primary endpoint in alopecia areata trial
Eli Lilly and Company and Incyte have reported positive top-line results from Phase III BRAVE-AA2 study of baricitinib, which demonstrated hair regrowth in adults with severe alopecia areata (AA). Discovered…
04 Mar 2021
Vir and GSK to halt enrolment in Covid-19 antibody trial
Vir Biotechnology and GlaxoSmithKline (GSK) have reported that an independent Data and Safety Monitoring Board (DSMB) has recommended halting enrolment in the VIR-7831 (GSK4182136) arm of the Phase III ACTIV-3…
03 Mar 2021
Amgen reports positive data from BLINCYTO study in leukaemia patients
Amgen has reported positive data from the Phase III study of BLINCYTO (blinatumomab) in paediatric patients with high-risk first-relapse B-cell precursor acute lymphoblastic leukaemia (B-ALL). A bispecific T-cell engager (BiTE)…